risperidone has been researched along with Depression, Involutional in 76 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present findings suggest that clozapine demonstrates superior antidepressant effects to quetiapine and comparable effects to olanzapine and risperidone in chronic schizophrenia regardless of presence of MDE." | 9.20 | Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. ( Caravaggio, F; Chung, JK; Fervaha, G; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mihashi, Y; Mulsant, B; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H, 2015) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 7.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "The aim of this study was to compare the treatment effectiveness between long-acting injectable risperidone and long-acting injectable first-generation antipsychotics among patients with bipolar disorder." | 7.83 | Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. ( Chang, CJ; Hsieh, MH; Tang, CH; Wu, CS, 2016) |
| "Prolactin levels returned to normal, and clinical symptoms of hyperprolactinemia resolved in all 3 patients after 2 weeks of tapering and discontinuation of risperidone." | 7.73 | Risperidone-induced hyperprolactinemia in adolescents: A case series. ( Madhusoodanan, S; Moise, D, 2006) |
| "MDD and dysphoria commonly occurred in this cohort of adult and adolescent Tourette's disorder patients treated with risperidone, particularly in patients with a previous history of depression." | 7.71 | Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. ( Annable, L; Dion, Y; Margolese, HC, 2002) |
| "Medicamentous hyperprolactinaemia is a well known side effect of risperidone." | 5.36 | Hyperprolactinaemia - a risperidone side-effect. ( Dadić-Hero, E; Grahovac, T; Medved, P; Pavesić-Radonja, A; Ruzić, K, 2010) |
| "To assess the benefit of short-term treatment with the atypical antipsychotic asenapine versus placebo on depressive symptoms in patients with acute schizophrenia in an exacerbated state." | 5.20 | Management of depressive symptoms in schizophrenia. ( Castle, DJ; Slott Jensen, JK, 2015) |
| "The present findings suggest that clozapine demonstrates superior antidepressant effects to quetiapine and comparable effects to olanzapine and risperidone in chronic schizophrenia regardless of presence of MDE." | 5.20 | Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. ( Caravaggio, F; Chung, JK; Fervaha, G; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mihashi, Y; Mulsant, B; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H, 2015) |
| "Forty-eight patients with remitted DSM-IV schizophrenia and comorbid major depression were randomized to placebo for 6 weeks or sertraline 50 mg for 4 weeks followed by sertraline 50 mg to 100 mg for 2 weeks for nonresponders." | 5.12 | Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication. ( Addington, D; Addington, J; Patten, S; Pierson, K, 2006) |
| "The Treatment of Early Onset Schizophrenia Spectrum Disorders Study is a publicly funded clinical trial designed to compare the therapeutic benefits, safety, and tolerability of risperidone, olanzapine, and molindone in youths with early-onset schizophrenia spectrum disorders." | 5.12 | Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. ( Ambler, D; Anderson, R; Findling, RL; Frazier, JA; Hamer, RM; Hlastala, SA; Hunt-Harrison, T; Lieberman, JA; Maloney, AE; McCLELLAN, J; Ritz, L; Sikich, L; Vitiello, B; Williams, E, 2007) |
| "There is some evidence that in the short term risperidone may reduce aggression and conduct problems in children and youths with disruptive behaviour disorders There is also evidence that this intervention is associated with significant weight gain." | 4.95 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2017) |
| "There is some limited evidence of efficacy of risperidone reducing aggression and conduct problems in children aged 5 to 18 with disruptive behaviour disorders in the short term." | 4.88 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2012) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 3.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "The aim of this study was to compare the treatment effectiveness between long-acting injectable risperidone and long-acting injectable first-generation antipsychotics among patients with bipolar disorder." | 3.83 | Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. ( Chang, CJ; Hsieh, MH; Tang, CH; Wu, CS, 2016) |
| "To identify the factors associated with newly prescribed, first-line, second-generation antipsychotics (SgAs) associated with weight gain-olanzapine, risperidone, and quetiapine." | 3.77 | Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. ( Arndt, S; Chrischilles, EA; Coryell, WH; Ellingrod, VL; Fiedorowicz, JG; Haynes, WG; Miller, del D; Prabhakar, M; Warren, L, 2011) |
| "Prolactin levels returned to normal, and clinical symptoms of hyperprolactinemia resolved in all 3 patients after 2 weeks of tapering and discontinuation of risperidone." | 3.73 | Risperidone-induced hyperprolactinemia in adolescents: A case series. ( Madhusoodanan, S; Moise, D, 2006) |
| "MDD and dysphoria commonly occurred in this cohort of adult and adolescent Tourette's disorder patients treated with risperidone, particularly in patients with a previous history of depression." | 3.71 | Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. ( Annable, L; Dion, Y; Margolese, HC, 2002) |
| "Antipsychotics are widely used in the treatment of major depressive disorder (MDD), but there has been no comprehensive meta-analytic assessment that examined their use as monotherapy and adjunctive therapy." | 3.01 | Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. ( Correll, CU; Hagi, K; Kane, JM; Kishimoto, T; Kurokawa, S, 2023) |
| "Pharmacological treatment of major depressive disorder is often inefficient, and multiple strategies are used for inadequate response to antidepressants." | 2.82 | Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. ( Chen, B; Ma, X; Wang, M; Yan, Y; Yang, X; Yin, L, 2022) |
| " Data were derived from an earlier study, designed to compare efficacy and tolerability of fixed dosage of extended-release venlafaxine, mitazapine, paroxetine, and risperidone, sodium valproate, buspirone, trazodone or thyroid hormone augmenting to paroxetine in those patients." | 2.78 | Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. ( Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C, 2013) |
| " There was no statistical significance among treatment arms in remission rates, secondary outcome measures, and adverse events." | 2.76 | A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. ( Calabrese, JR; Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C, 2011) |
| "274 outpatient adults with major depressive disorder that was suboptimally responsive to antidepressant therapy." | 2.73 | Risperidone for treatment-refractory major depressive disorder: a randomized trial. ( Canuso, CM; Gharabawi-Garibaldi, GM; Kosik-Gonzalez, C; Kujawa, MJ; Mahmoud, RA; Pandina, GJ; Turkoz, I, 2007) |
| "Risperidone is an atypical antipsychotic drug with combined dopamine-2/serotonin-2 (D(2)/5-HT(2)) antagonist activity that has been effective in reducing cocaine use in some animal studies." | 2.73 | A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. ( Angarita, GA; Culhane, MA; Evins, AE; Huang, KL; Lee, SH; Loebl, T; Logvinenko, T; Nino, J; Pachas, GN, 2008) |
| "Risperidone is an atypical antipsychotic that displays antidepressant properties due to its activity at various serotonergic and dopaminergic receptors." | 2.47 | Use of risperidone as augmentation treatment for major depressive disorder. ( Brown, JN; Brown, LT; Owenby, RK, 2011) |
| "In risperidone-treated boys, SSRI use is associated with reduced longitudinal growth, particularly in those undergoing puberty." | 1.48 | Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys. ( Calarge, CA; Garcia, JM; Karaviti, L; Mills, JA; Teixeira, AL; Zemel, BS, 2018) |
| "Risperidone monotherapy was the primary antipsychotic treatment." | 1.43 | Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes. ( Badner, JA; Bishop, JR; Harris, MS; Keshavan, MS; Nimgaonkar, VL; Patel, SR; Prasad, KM; Reilly, JL; Stevenson, JM; Sweeney, JA; Weiden, PJ, 2016) |
| " "Instead of the medicament prescribed, a GP doctor is allowed to prescribe an alternative medicament of the same efficacy in the dosage of an adequate strength" (taken from the specialist medical report form)." | 1.36 | Side-effects of generic. ( Dadić-Hero, E; Graovac, M; Grzeta, IR; Medved, P; Ruzić, K; Tatalović-Vorkapić, S, 2010) |
| "Medicamentous hyperprolactinaemia is a well known side effect of risperidone." | 1.36 | Hyperprolactinaemia - a risperidone side-effect. ( Dadić-Hero, E; Grahovac, T; Medved, P; Pavesić-Radonja, A; Ruzić, K, 2010) |
| " However, no correlation between prolactin levels and dosage could be found." | 1.32 | [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003) |
| "Converging evidence indicates that, in controlled drug trials, individuals receiving novel antipsychotic medications have fewer adverse effects than those receiving conventional antipsychotic medications." | 1.31 | Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. ( Bromet, EJ; Davidson, M; Rabinowitz, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 40 (52.63) | 29.6817 |
| 2010's | 30 (39.47) | 24.3611 |
| 2020's | 6 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 2 |
| Cai, G | 1 |
| Fang, F | 1 |
| Li, W | 1 |
| Fan, M | 1 |
| Lian, J | 1 |
| Qiu, Y | 1 |
| Xu, X | 1 |
| Lv, X | 1 |
| Li, Y | 1 |
| Zheng, R | 1 |
| Wang, Y | 2 |
| Zhang, G | 1 |
| Liu, Z | 1 |
| Huang, Z | 1 |
| Zhang, L | 1 |
| Kishimoto, T | 1 |
| Hagi, K | 1 |
| Kurokawa, S | 1 |
| Kane, JM | 1 |
| Correll, CU | 1 |
| Scott, F | 1 |
| Hampsey, E | 1 |
| Gnanapragasam, S | 1 |
| Carter, B | 1 |
| Marwood, L | 1 |
| Taylor, RW | 1 |
| Emre, C | 1 |
| Korotkova, L | 1 |
| Martín-Dombrowski, J | 1 |
| Cleare, AJ | 1 |
| Young, AH | 1 |
| Strawbridge, R | 1 |
| Yan, Y | 1 |
| Yang, X | 1 |
| Wang, M | 1 |
| Chen, B | 1 |
| Yin, L | 1 |
| Ma, X | 1 |
| Maximo, JO | 1 |
| Nelson, EA | 1 |
| Armstrong, WP | 1 |
| Kraguljac, NV | 1 |
| Lahti, AC | 1 |
| Ou, H | 1 |
| Chang, HA | 1 |
| Kao, YC | 1 |
| Tzeng, NS | 1 |
| Loy, JH | 2 |
| Merry, SN | 2 |
| Hetrick, SE | 2 |
| Stasiak, K | 2 |
| Nesvåg, R | 1 |
| Bramness, JG | 1 |
| Handal, M | 1 |
| Hartz, I | 1 |
| Hjellvik, V | 1 |
| Skurtveit, S | 1 |
| Calarge, CA | 1 |
| Mills, JA | 1 |
| Karaviti, L | 1 |
| Teixeira, AL | 1 |
| Zemel, BS | 1 |
| Garcia, JM | 1 |
| Dean, B | 1 |
| Gibbons, A | 1 |
| Gogos, A | 1 |
| Udawela, M | 1 |
| Thomas, E | 1 |
| Scarr, E | 1 |
| Dias Alves, M | 1 |
| Micoulaud-Franchi, JA | 1 |
| Simon, N | 1 |
| Vion-Dury, J | 1 |
| Wu, Z | 2 |
| Chen, J | 3 |
| Yuan, C | 2 |
| Hong, W | 2 |
| Peng, D | 1 |
| Zhang, C | 1 |
| Cao, L | 2 |
| Fang, Y | 2 |
| Pandina, G | 1 |
| Turkoz, I | 3 |
| Bossie, C | 1 |
| Wen, XJ | 1 |
| Wang, LM | 1 |
| Liu, ZL | 1 |
| Huang, A | 1 |
| Liu, YY | 1 |
| Hu, JY | 1 |
| Makkos, Z | 1 |
| Lin, CY | 1 |
| Tsai, GE | 1 |
| Wang, HS | 1 |
| Wu, YH | 1 |
| Chiou, CC | 1 |
| Wu, VY | 1 |
| Lane, HY | 1 |
| Castle, DJ | 1 |
| Slott Jensen, JK | 1 |
| Pietrzak, RH | 1 |
| Rosenheck, RA | 1 |
| Cramer, JA | 1 |
| Vessichio, JC | 1 |
| Tsai, J | 1 |
| Southwick, SM | 1 |
| Krystal, JH | 1 |
| Nakajima, S | 1 |
| Takeuchi, H | 1 |
| Fervaha, G | 1 |
| Plitman, E | 1 |
| Chung, JK | 1 |
| Caravaggio, F | 1 |
| Iwata, Y | 1 |
| Mihashi, Y | 1 |
| Gerretsen, P | 1 |
| Remington, G | 1 |
| Mulsant, B | 1 |
| Graff-Guerrero, A | 1 |
| Kazdal, H | 1 |
| Kanat, A | 1 |
| Sen, A | 1 |
| Kirbas, S | 1 |
| Ardic, G | 1 |
| Tufekci, A | 1 |
| Ersoz, T | 1 |
| Cawkwell, P | 1 |
| Lawler, A | 1 |
| Maneta, E | 1 |
| Coffey, BJ | 1 |
| Stevenson, JM | 1 |
| Reilly, JL | 1 |
| Harris, MS | 1 |
| Patel, SR | 1 |
| Weiden, PJ | 1 |
| Prasad, KM | 1 |
| Badner, JA | 1 |
| Nimgaonkar, VL | 1 |
| Keshavan, MS | 1 |
| Sweeney, JA | 1 |
| Bishop, JR | 1 |
| Wu, CS | 1 |
| Hsieh, MH | 1 |
| Tang, CH | 1 |
| Chang, CJ | 1 |
| Ryan, PB | 1 |
| Schuemie, MJ | 1 |
| Ramcharran, D | 1 |
| Stang, PE | 1 |
| Laenger, A | 1 |
| Leicht, G | 1 |
| Schule, C | 1 |
| Baghai, TC | 1 |
| Lindhaus, S | 1 |
| Rupprecht, R | 1 |
| Keitner, GI | 1 |
| Garlow, SJ | 1 |
| Ryan, CE | 1 |
| Ninan, PT | 1 |
| Solomon, DA | 1 |
| Nemeroff, CB | 1 |
| Keller, MB | 1 |
| Reeves, H | 1 |
| Batra, S | 1 |
| May, RS | 1 |
| Zhang, R | 1 |
| Dahl, DC | 1 |
| Li, X | 1 |
| Yoshimura, R | 1 |
| Umene-Nakano, W | 1 |
| Ueda, N | 1 |
| Ikenouchi-Sugita, A | 1 |
| Hori, H | 1 |
| Nakamura, J | 1 |
| Pandina, GJ | 2 |
| Revicki, DA | 1 |
| Kleinman, L | 1 |
| Wu, JH | 1 |
| Kujawa, MJ | 2 |
| Mahmoud, R | 1 |
| Gharabawi, GM | 1 |
| Takahashi, T | 1 |
| Wood, SJ | 1 |
| Yung, AR | 1 |
| Soulsby, B | 1 |
| McGorry, PD | 1 |
| Suzuki, M | 1 |
| Kawasaki, Y | 1 |
| Phillips, LJ | 1 |
| Velakoulis, D | 1 |
| Pantelis, C | 1 |
| Benazzi, F | 1 |
| Berk, M | 1 |
| Frye, MA | 1 |
| Wang, W | 1 |
| Barraco, A | 1 |
| Tohen, M | 1 |
| Ruzić, K | 2 |
| Medved, P | 2 |
| Dadić-Hero, E | 2 |
| Graovac, M | 1 |
| Tatalović-Vorkapić, S | 1 |
| Grzeta, IR | 1 |
| Grahovac, T | 1 |
| Pavesić-Radonja, A | 1 |
| Gao, K | 2 |
| Kemp, DE | 1 |
| Komossa, K | 1 |
| Depping, AM | 1 |
| Gaudchau, A | 1 |
| Kissling, W | 1 |
| Leucht, S | 1 |
| Owenby, RK | 1 |
| Brown, LT | 1 |
| Brown, JN | 1 |
| Baez, MA | 1 |
| Avery, J | 1 |
| Xu, Y | 1 |
| Yi, Z | 1 |
| Jiang, K | 1 |
| Cui, X | 1 |
| Calabrese, JR | 2 |
| Prabhakar, M | 1 |
| Haynes, WG | 1 |
| Coryell, WH | 1 |
| Chrischilles, EA | 1 |
| Miller, del D | 1 |
| Arndt, S | 1 |
| Ellingrod, VL | 1 |
| Warren, L | 1 |
| Fiedorowicz, JG | 1 |
| Rapinesi, C | 1 |
| Serata, D | 1 |
| Del Casale, A | 1 |
| Kotzalidis, GD | 2 |
| Romano, S | 1 |
| Milioni, M | 1 |
| Capezzuto, S | 1 |
| Carbonetti, P | 1 |
| Angeletti, G | 1 |
| Fensore, C | 1 |
| Tatarelli, R | 2 |
| Girardi, P | 2 |
| Morag, A | 1 |
| Oved, K | 1 |
| Gurwitz, D | 1 |
| Margolese, HC | 1 |
| Annable, L | 1 |
| Dion, Y | 1 |
| Gupta, SC | 1 |
| Jagadheesan, K | 1 |
| Basu, S | 1 |
| Paul, SE | 1 |
| Fric, M | 1 |
| Laux, G | 1 |
| Tani, K | 1 |
| Takei, N | 1 |
| Kawai, M | 1 |
| Suzuki, K | 1 |
| Sekine, Y | 1 |
| Toyoda, T | 1 |
| Minabe, Y | 1 |
| Mori, N | 1 |
| Eren, I | 1 |
| Ozcankaya, R | 1 |
| Altinyazar, V | 1 |
| Segal, J | 1 |
| Szabo, CP | 1 |
| du Toit, J | 1 |
| Rachid, F | 1 |
| Bertschy, G | 1 |
| Bondolfi, G | 1 |
| Aubry, JM | 1 |
| Galynker, I | 1 |
| Khan, A | 1 |
| Grebchenko, Y | 1 |
| Ten, A | 1 |
| Malaya, L | 1 |
| Yanowitch, P | 1 |
| Cohen, LJ | 1 |
| Marazziti, D | 1 |
| Dell'Osso, B | 1 |
| Del Tacca, M | 1 |
| Lattanzi, L | 1 |
| Lastella, M | 1 |
| Di Paolo, A | 1 |
| Mungai, F | 1 |
| Danesi, R | 1 |
| Menichetti, F | 1 |
| Dell'osso, L | 1 |
| Cassano, GB | 1 |
| Deberdt, WG | 1 |
| Dysken, MW | 1 |
| Rappaport, SA | 1 |
| Feldman, PD | 1 |
| Young, CA | 1 |
| Hay, DP | 1 |
| Lehman, DL | 1 |
| Dossenbach, M | 1 |
| Degenhardt, EK | 1 |
| Breier, A | 1 |
| Manfredi, G | 1 |
| Lazanio, S | 1 |
| Ruberto, A | 1 |
| Kozian, R | 1 |
| Goldman, S | 1 |
| Nierenberg, AA | 1 |
| Ostacher, MJ | 1 |
| Ketter, TA | 1 |
| Marangell, LB | 1 |
| Miklowitz, DJ | 1 |
| Miyahara, S | 1 |
| Bauer, MS | 1 |
| Thase, ME | 1 |
| Wisniewski, SR | 1 |
| Sachs, GS | 1 |
| Rasmussen, K | 1 |
| Zink, M | 1 |
| Knopf, U | 2 |
| Argiriou, S | 1 |
| Kuwilsky, A | 1 |
| Madhusoodanan, S | 2 |
| Moise, D | 1 |
| Gabriel, A | 1 |
| Pierson, K | 1 |
| Addington, D | 1 |
| Addington, J | 1 |
| Patten, S | 1 |
| McCLELLAN, J | 1 |
| Sikich, L | 1 |
| Findling, RL | 1 |
| Frazier, JA | 1 |
| Vitiello, B | 1 |
| Hlastala, SA | 1 |
| Williams, E | 1 |
| Ambler, D | 1 |
| Hunt-Harrison, T | 1 |
| Maloney, AE | 1 |
| Ritz, L | 1 |
| Anderson, R | 1 |
| Hamer, RM | 1 |
| Lieberman, JA | 1 |
| Marchesi, C | 1 |
| Tonna, M | 1 |
| Maggini, C | 1 |
| Mahmoud, RA | 1 |
| Kosik-Gonzalez, C | 1 |
| Canuso, CM | 1 |
| Gharabawi-Garibaldi, GM | 1 |
| Philip, NS | 1 |
| Carpenter, LL | 1 |
| Tyrka, AR | 1 |
| Price, LH | 1 |
| Loebl, T | 1 |
| Angarita, GA | 1 |
| Pachas, GN | 1 |
| Huang, KL | 1 |
| Lee, SH | 1 |
| Nino, J | 1 |
| Logvinenko, T | 1 |
| Culhane, MA | 1 |
| Evins, AE | 1 |
| Gupta, S | 1 |
| Frank, B | 1 |
| Hubrich-Ungureanu, P | 1 |
| Thome, J | 1 |
| Rubin, NJ | 1 |
| Arceneaux, JM | 1 |
| Weizman, R | 1 |
| Weizman, A | 1 |
| Rabinowitz, J | 1 |
| Bromet, EJ | 1 |
| Davidson, M | 1 |
| Freudenreich, O | 1 |
| Hoy, JS | 1 |
| Alexander, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glutamate, Brain Connectivity and Duration of Untreated Psychosis[NCT02034253] | 134 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study in Medication-naïve First Episode Psychosis Patients[NCT03442101] | 156 participants (Anticipated) | Observational | 2018-04-01 | Recruiting | |||
| Neuroimaging Biomarker-Guided Personalized Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Major Depressive Episode in Adolescents and Young Adults With Mood Disorders: A Randomized, Double-Blind, Controlled Study[NCT05465928] | 120 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | |||
| A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy[NCT00095134] | Phase 3 | 630 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine Positive Control in Subjects With an Acute Exacerbation of Schizophrenia[NCT00156117] | Phase 3 | 417 participants (Actual) | Interventional | 2005-05-12 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia[NCT00156104] | Phase 3 | 460 participants (Actual) | Interventional | 2005-07-01 | Completed | ||
| Efficacy of Risperidone in the Management of Suicidality in Major Depressive Disorder[NCT00167154] | Phase 3 | 30 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Bipolar Disorder and Oxidative Stress Injury Mechanism - Clinical Big Data Analysis Based on Machine Learning[NCT03949218] | 3,702 participants (Actual) | Observational | 2018-11-20 | Completed | |||
| Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)[NCT00012558] | 5,000 participants | Interventional | 1998-09-30 | Completed | |||
| Treatment of Schizophrenia and Related Disorders in Children and Adolescents[NCT00053703] | Phase 4 | 116 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| A Double-Blind, Placebo-Controlled Study of the Effects of Risperdal Consta on Brain Reward Circuitry, Craving and Cocaine Use in Active Cocaine Dependence[NCT00385801] | Phase 2 | 31 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Barnes Akathisia Scale is a clinician rated scale which considers information based on observation of the participant as well as participant report. The scale includes 3 items rated between 0- none to 3 severe and 1 summary item rated between 0 none to 5 severe. All items are summed to obtain the total score. The minimal total score is 0 and the maximal score is 14 with higher scores reflecting more severe akathisia. A score of 4 or more is clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | 0.19 |
| Risperidone | 0.41 |
| Molindone | 1.23 |
Change from baseline in Body Mass Index Change, kg/m2, at week 8, last observation was carried forward for individuals who withdrew from treatment early. (NCT00053703)
Timeframe: 8 weeks
| Intervention | kg/m2 (Mean) |
|---|---|
| Olanzapine | 1.27 |
| Risperidone | 2.20 |
| Molindone | 0.15 |
The PANSS (described above) includes 7 items that reflect negative psychotic symptoms such as amotivation and social withdrawal. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -5.3 |
| Risperidone | -5.1 |
| Molindone | -5.8 |
The PANSS (described above) includes 7 items that reflect positive psychotic symptoms such as hallucinations and delusions. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -8.9 |
| Risperidone | -8.4 |
| Molindone | -8.8 |
Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores > that 60 are considered clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -26.6 |
| Risperidone | -23.7 |
| Molindone | -27.0 |
change in weight from baseline to week 8 in kg (NCT00053703)
Timeframe: 8 weeks
| Intervention | Kg (Mean) |
|---|---|
| Olanzapine | 6.12 |
| Risperidone | 3.64 |
| Molindone | 0.34 |
The University of Minnesota Cocaine Craving Scale was performed to assess cocaine craving. The scale contains 1 continuous scale for intensity and 2 categorical scales for frequency and duration of craving episodes. The continuous scale for craving intensity ranges from 0 (no craving at all in the past week) to 10 (a great deal of craving in the past week) (NCT00385801)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | NA |
| Risperidone | NA |
After randomization, participants provided urine samples every week for the first 3 weeks and then every 2 weeks for 8 weeks, up to 7 samples per participant. The average visits with cocaine negative urine samples per participant are reported below (NCT00385801)
Timeframe: 12 weeks
| Intervention | visit with negative UBE (Mean) |
|---|---|
| Placebo | 1.81 |
| Risperidone Consta | 0.87 |
13 reviews available for risperidone and Depression, Involutional
| Article | Year |
|---|---|
Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2023 |
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression.
Topics: Adult; Aripiprazole; Depression; Depressive Disorder, Major; Humans; Ketamine; Risperidone | 2023 |
Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Netwo | 2022 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2017 |
Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; | 2014 |
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
Topics: Adult; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depr | 2011 |
Second-generation antipsychotics for major depressive disorder and dysthymia.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive | 2010 |
Use of risperidone as augmentation treatment for major depressive disorder.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Dopamine Antagonists; Drug Therapy, Combination; H | 2011 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2012 |
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde | 2004 |
Creating more effective antidepressants: clues from the clinic.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dep | 2006 |
Augmentation of antidepressants with atypical antipsychotics: a review of the current literature.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder, Major; | 2008 |
Use of atypical antipsychotics in mood disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Depres | 2001 |
14 trials available for risperidone and Depression, Involutional
| Article | Year |
|---|---|
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cy | 2013 |
Impact of self-reported juvenile abuse on treatment outcome in patients with major depressive disorder.
Topics: Adolescent; Adult; Adult Survivors of Child Abuse; Aged; Antidepressive Agents; Depressive Disorder, | 2013 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Depressive | 2015 |
A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-B | 2009 |
Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Diagnostic and Stati | 2008 |
Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Bipolar Disorder; Cognitive Behavioral Therapy; Co | 2009 |
A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
Topics: Buspirone; China; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Co | 2011 |
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaze | 2005 |
Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Di | 2006 |
Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depressive Disorder, Ma | 2006 |
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Depressi | 2007 |
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Do | 2007 |
A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men.
Topics: Adult; Antipsychotic Agents; Cocaine-Related Disorders; Delayed-Action Preparations; Depressive Diso | 2008 |
49 other studies available for risperidone and Depression, Involutional
| Article | Year |
|---|---|
Discovery of Novel and Potent
Topics: Action Potentials; Allosteric Regulation; Animals; Antidepressive Agents; Binding Sites; Cell Surviv | 2021 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Risperidone-Induced Acute Urinary Retention in a Patient With Major Depressive Disorder With Psychotic Features: a Case Report.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Humans; Psychotic Disorders; Risperidone; Urinary | 2021 |
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Comorbidity; Depressive Dis | 2018 |
Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys.
Topics: Adolescent; Antipsychotic Agents; Body Mass Index; Child; Child, Preschool; Depressive Disorder, Maj | 2018 |
Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Bipolar Disorder; B | 2018 |
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Cloz | 2018 |
[Antipsychotics -- do they exist?].
Topics: Adaptation, Psychological; Affect; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Cor | 2014 |
Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dibenz | 2014 |
Elucidating the transdiagnostic dimensional structure of trauma-related psychopathology: Findings from VA cooperative study 504 - risperidone treatment for military service related chronic post traumatic stress disorder.
Topics: Adult; Aged; Antipsychotic Agents; Arousal; Comorbidity; Depressive Disorder, Major; Factor Analysis | 2015 |
A novel clinical observation in neuroleptic malignant-like syndrome: first demonstration of early progression of hydrocephalus.
Topics: Aged; Antipsychotic Agents; Depressive Disorder, Major; Disease Progression; Fatal Outcome; Female; | 2015 |
Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder | 2016 |
Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Female; Genome-Wide Assoc | 2016 |
Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Comparative Effectiveness Research; Delay | 2016 |
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Bipolar Disorde | 2017 |
Electroconvulsive therapy in a patient with concomitant depression and charcot-marie-tooth disease.
Topics: Aged; Charcot-Marie-Tooth Disease; Combined Modality Therapy; Comorbidity; Contraindications; Depres | 2008 |
Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Depress | 2008 |
Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Double-Blind M | 2009 |
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Diso | 2009 |
Side-effects of generic.
Topics: Affective Disorders, Psychotic; Aged; Antipsychotic Agents; Cost Savings; Croatia; Depressive Disord | 2010 |
Hyperprolactinaemia - a risperidone side-effect.
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Depressive Disorder, Major; Dose-Response Rela | 2010 |
Improvement in drug-induced parkinsonism with electroconvulsive therapy.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Depressive Disorder, Major; Electroconvulsive Ther | 2011 |
Adjunctive antipsychotics for major depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; | 2011 |
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.
Topics: Academic Medical Centers; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive | 2011 |
Electroconvulsive therapy in a physically restrained man with comorbid major depression, severe agoraphobia with panic disorder, and histrionic personality disorder.
Topics: Adult; Agoraphobia; Antimanic Agents; Antipsychotic Agents; Depressive Disorder, Major; Electroconvu | 2012 |
Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Antineoplastic Agents; Antipsychotic Agents; Cell D | 2013 |
Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depression; Depressive Disorder, Major; Dose-Response | 2002 |
Risperidone-induced galactorrhoea: a case series.
Topics: Adult; Depressive Disorder, Major; Female; Galactorrhea; Humans; Risperidone; Selective Serotonin Re | 2003 |
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2003 |
Augmentation of milnacipran by risperidone in treatment for major depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cyclopropanes; Depressi | 2004 |
Risperidone-induced rabbit syndrome in mood disorder.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Diagnosis, Differential; Hallucinations; Humans; M | 2004 |
Child and adolescent electroconvulsive therapy: a case report.
Topics: Adolescent; Antipsychotic Agents; Child; Cognition Disorders; Combined Modality Therapy; Depressive | 2004 |
Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression.
Topics: Adult; Aged; Antipsychotic Agents; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Diben | 2005 |
Effectiveness of risperidone in psychogenic stiff neck.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Female; Humans; Middle Aged; Risperidone; Torticol | 2005 |
Genotype A1/A2 associated with neuroleptic malignant syndrome.
Topics: Adult; Alleles; Antipsychotic Agents; Citalopram; Depressive Disorder, Major; DNA Primers; Humans; M | 2005 |
Postpartum depression without delivering a child?
Topics: Alprazolam; Anti-Anxiety Agents; Depression, Postpartum; Depressive Disorder, Major; Diagnostic and | 2005 |
[Brief case report. Duloxetine in Cotard syndrome].
Topics: Affective Disorders, Psychotic; Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; | 2005 |
Possible antipsychotic effect of fluvoxamine.
Topics: Antipsychotic Agents; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Drug Admi | 2005 |
A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Comorbidity; Depressive Disorder, Maj | 2006 |
Risperidone-induced hyperprolactinemia in adolescents: A case series.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Depressive Disorder, Major; Diagnostic and Statistica | 2006 |
Changes in plasma cholesterol in mood disorder patients: does treatment make a difference?
Topics: Acute Disease; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; A | 2007 |
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.
Topics: Adolescent; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Antipsychotic Agents; B | 2009 |
Summaries for patients. Can adding risperidone to antidepressant therapy relieve persistent symptoms of depression?
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Do | 2007 |
Risperidone-associated galactorrhea in a male teenager.
Topics: Adolescent; Antipsychotic Agents; Depressive Disorder, Major; Galactorrhea; Humans; Male; Risperidon | 2001 |
[Paroxetine augmentation with risperidone in therapy-resistant depression].
Topics: Aged; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 2001 |
Intractable depression or psychosis.
Topics: Aged; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; | 2001 |
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder, Majo | 2001 |
Exacerbation of idiopathic priapism with risperidone-citalopram combination.
Topics: Adrenergic Antagonists; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cital | 2002 |
Rabbit syndrome secondary to risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; Depressive Disorder, M | 2002 |